Dr. John (Jack) Geltosky, Ph.D., is an Independent Director of Sophiris Bio Inc., since September 29, 2008. He is currently Managing Director of JEG and Associates, LLC, a business development consultancy firm focused on biotech and pharmaceuticals, a position he has held since September 2011. From October 2007 to September 2011, Dr. Geltosky served as Senior Vice President of Business Development for Arizona Technology Enterprises, the technology transfer arm of Arizona State University. Prior to Arizona Technology Enterprises, Dr. Geltosky was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb, or BMS, a public pharmaceuticals company, where he was responsible for the acquisition and licensing of, as well as coordinating due diligence efforts on, potential in- and out-licensing candidates. Prior to joining BMS, Dr. Geltosky was President and Chief Executive Officer of Message Pharmaceuticals, Inc., a pharmaceutical company. Prior to Message Pharmaceuticals, he was Vice President, Scientific Licensing, Worldwide Business Development at SmithKline Beecham (now GlaxoSmithKline). For 10 years, Dr. Geltosky held roles of increasing responsibility within Johnson & Johnson. Dr. Geltosky began his career as a research scientist at E.I. DuPont. Dr. Geltosky holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology. Based on Dr. Geltosky’s senior management experience in the biotechnology industry and his scientific background as well as his experience evaluating drug candidates, the Board believes Dr. Geltosky has the appropriate set of skills to serve on our Board.
John Geltosky is 69, he's been the Independent Director of Sophiris Bio Inc since 2008. There are 1 older and 5 younger executives at Sophiris Bio Inc. The oldest executive at Sophiris Bio Inc is Lars Ekman, 70, who is the Chairman of the Board.
John's mailing address filed with the SEC is 1258 Prospect St, La Jolla, CA 92037, USA.
Over the last 11 years, insiders at Sophiris Bio Inc have traded over $592,052 worth of Sophiris Bio Inc stock and bought 1,642,180 units worth $8,144,540 . The most active insiders traders include Capital, Llc Boxer Asset Ma..., Capital, Llc Boxer Asset Ma..., and William R Rohn. On average, Sophiris Bio Inc executives and independent directors trade stock every 155 days with the average trade being worth of $0. The most recent stock trade was executed by Randall E Woods on 19 September 2018, trading 10,000 units of SPHS stock currently worth $26,300.
Sophiris Bio Inc executives and other stock owners filed with the SEC include: